Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abbott Laboratories SEC filings document an Illinois healthcare company with common shares listed under ABT and operations in diagnostics, medical devices, nutritionals and branded generic medicines. The filings include Form 8-K reports on operating results, non-GAAP financial measures, material agreements, acquisition-related events, debt financing and amendments to corporate governance documents.
Abbott's proxy and event filings cover shareholder voting matters, board and bylaw governance, executive compensation, capital-structure disclosures and clinical or regulatory disclosures. The filing record also documents the completed Exact Sciences acquisition and the addition of cancer diagnostics to Abbott's broader diagnostic portfolio.
Abbott Laboratories vice president and controller John A. McCoy Jr. reported multiple transactions in Abbott common shares. On March 2, 2026, he completed an open-market sale of 585 shares at $115.58 per share. On February 27, 2026, he disposed of 1,142 shares at $116.26 per share to cover tax obligations by delivering shares rather than cash. After these transactions, he held 24,628 common shares directly. A separate indirect holding of 58 shares was reported in a Profit Sharing Trust, with the balance noted as of February 27, 2026.
Abbott Laboratories Chairman and CEO Robert B. Ford reported a tax-related share disposition. On February 27, 2026, he disposed of 30,308 common shares at $116.26 per share through a tax-withholding transaction, a method used to satisfy tax obligations rather than an open-market sale.
After this transaction, Ford held 306,461 common shares directly. In addition, 216,203 common shares were held indirectly through the Ford Family Trust, where he serves as co-trustee, reflecting an additional layer of beneficial ownership separate from his direct holdings.
ABBOTT LABORATORIES executive Lisa D. Earnhardt, EVP and Group President, reported a tax-withholding disposition of 8,577 common shares on February 27, 2026. The shares were valued at $116.26 per share for tax purposes, and she held 90,407 shares directly after this transaction.
Abbott Laboratories executive Elizabeth C. Cushman reported two share dispositions. On March 2, she completed an open-market sale of 263 common shares at $115.58 per share, leaving her with 38,573 shares held directly.
On February 27, she disposed of 1,421 shares at $116.26 per share to cover tax obligations through a tax-withholding transaction, rather than a traditional sale. Both transactions involve Abbott common shares without par value and reflect routine insider activity by the company’s EVP, General Counsel and Secretary.
Abbott Laboratories EVP and CFO Philip P. Boudreau reported a tax-related share disposition. On February 27, 2026, 7,441 common shares were surrendered at $116.26 per share to cover tax withholding obligations, a non-open-market transaction. After this, he directly held 71,172 common shares and indirectly held 366 shares through a Profit Sharing Trust as of that date.